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OBJECTIVES: To develop an epidemiological and economic
model of ﬁrst-onset cardiovascular disease (CVD, comprising
myocardial infarction and ischemic stroke) in Korea that can
be applied to cost-effectiveness analyses of interventions.
METHODS: KIMCHI is a Markov model with yearly cycles and
the health states ‘Alive without CVD’, ‘Alive with CVD’, ‘Dead
from CVD’ and ‘Dead from non-CVD causes’. It is populated
with 5270 CVD-naïve subjects aged 18 years from the 2005
Korea National Health and Nutritional Examination Survey.
Annual probabilities of CVD are estimated for each individual
using the Asian-speciﬁc risk equation by Wu, the covariates for
which are: sex, age, total cholesterol (TC), systolic blood pres-
sure (SBP), smoking, diabetes and body mass index (BMI). Age-
and-sex-speciﬁc annual probabilities of death are based on
national health data. To illustrate the function of KIMCHI,
follow-up was simulated of Koreans aged 55 years until death
or age 99 and the cost-effectiveness of atorvastatin for the
primary prevention of CVD assessed using decision analysis. The
TC-reducing efﬁcacy and cost of atorvastatin were drawn from a
meta-analysis and current drug pricing schedules, respectively.
CVD costs were provided by the Korean Health Insurance
Review and Assessment Services. A 5% annual discount rate was
applied. RESULTS: KIMCHI predicted that 30.4% and 18.2%
of CVD-naïve Koreans currently aged 55 years will develop
non-fatal and fatal CVD, respectively, by age 99. Atorvastatin
was predicted to reduce these ﬁgures to 25.4% and 15.4%,
corresponding to numbers needed to treat of 20 and 36 to
prevent non-fatal and fatal CVD, respectively. The estimated
ICERs were 21.8 million KW/YoLS and 17.4 million KW/QALY
saved. CONCLUSIONS: KIMCHI is a contemporary epidemio-
logical and economic model of CVD in Korea that can predict
future patterns of disease and be applied to cost-effectiveness
analyses of interventions that alter any of TC, SBP, smoking,
diabetes and BMI.
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OBJECTIVES: To estimate the long- and short-term costs and
effects of 2 year treatment with high-dose atorvastatin (80 mg)
versus medium dose simvastatin (40 mg) in patients with acute
coronary syndrome (ACS) and to analyse risk levels where
therapy may be expected to be cost-effective. METHODS: Efﬁ-
cacy is estimated based on a preliminary Bayesian meta-analysis
linking decrease in LDL cholesterol levels to decreases in sec-
ondary cardiac events (MI, stroke, cardiovascular death)
drawing data from the A to Z and PROVE-IT trials and using
priors from other statin trials. The Markov model combines
estimates of the occurrence of later events; UK cost data; and
quality of life. A baseline risk of 12% is taken from the CURE
trial, an ACS study with risks that lie between those in the
international ACS registry (GRACE) and those of the two
statin trials. RESULTS: At a 12% event risk during the ﬁrst 6
months and a 4% risk during later months, and with an esti-
mated 10% additional efﬁcacy of high-dose atorvastatin, the
estimated NNT to avoid one event is approximately 50. Costs
per life year gained and costs per QALY are estimated at below
£10,000. Costs per QALY are anticipated to be over £30,000
when the 6-month risk of cardiac events is less than 1% (cor-
responding with a 10-year risk of >20%), or when the esti-
mated additional risk reduction due to high-dose atorvastatin is
less than 3%. CONCLUSIONS: Based on our preliminary ﬁnd-
ings, high-dose atorvastatin is estimated to be cost-effective in
comparison to medium dose simvastatin in ACS patients. As
the analysis presented here is preliminary, the results may alter
following reconsideration of the priors. In addition, subsequent
probabilistic analysis will be used to explore uncertainties
around the estimates.
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OBJECTIVES: To determine the balance between risks and ben-
eﬁts of aneurysm occlusion in elderly patients with subarachnoid
haemorrhage (SAH), as function of patient characteristics and
aneurysm characteristics. The analysis focused mainly on the
effects of patient age, clinical condition and day of admission
after SAH. METHODS: With Markov model Monte Carlo simu-
lation we evaluated health gains, in quality-adjusted life years
(QALY), additional costs, and incremental cost-effectiveness
ratios (ICER) of aneurysm occlusion in 192 subgroups of
patients. Subgroups were deﬁned by age (70–74, 75–79, 80–84,
85+ years), neurological condition at admission (poor or good),
day of admission after SAH (<4, 4–10, 11–21 days), gender,
aneurysm size (<10 mm or 10 mm) and aneurysm location
(anterior or posterior circulation). RESULTS: In patients admit-
ted in poor condition 10 days after SAH, and patients older
than 80 years, admitted in poor condition 4 days after SAH,
aneurysm occlusion implied QALY loss as well as increased costs,
regardless of aneurysm size and location. The ICER of occlusion
was better than €50,000/QALY only in women aged 70–79
years, and men aged 70–74 years, admitted in good condition in
<4 days. Occlusion was both beneﬁcial and cost-saving in women
aged 70–74 years, admitted in good condition in <4 days, with a
small posterior aneurysm. CONCLUSIONS: Occlusion of rup-
tured intracranial aneurysms instead of conservative treatment
improves outcome in some elderly patients, but not in all, and
will often incur unacceptably high costs. The occlusion beneﬁts
of reduced risks of rebleeding and recurrent SAH only ensure the
ﬁnal balance is positive when patients can proﬁt from them, in
fair health, over several years. Thus, beyond some patient age,
occlusion should no longer be viewed as standard treatment,
but as option, viable only in patients with a prolonged life
expectancy.
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OBJECTIVES: Hypertension is a major risk factor for cardio-
vascular disease and a leading cause of morbidity and mortality.
The present study evaluates irbesartan in relation to losartan
and valsartan in the treatment of hypertension in Greece.
METHODS: A Markov model was constructed with eight health
states, including: hypertension, myocardial infarction, post-MI,
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